Are clinical trials safe?

Yes. Every study on QualifiedStudies is reviewed and approved by an Institutional Review Board (IRB) and conducted under FDA regulations. Research sites are HIPAA-covered entities, and you can withdraw at any time for any reason.

Do I get paid to participate in a clinical trial?

Most studies offer compensation for your time and travel. The amount varies by study length and visit schedule, and is disclosed up front before you enroll.

Is my health information kept private?

Yes. Your information is encrypted, never sold, and only shared with the specific research site you choose to apply to. Our handling of your data is governed by our Consumer Health Data Privacy Policy; the research sites you're matched with are HIPAA-covered entities.

How do I qualify for a clinical trial?

Take our free 60-second eligibility quiz. Enter your ZIP code, condition, and a few health details, and we'll match you with research sites near you that are actively enrolling participants.

A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases

NCT ID: NCT07873931
Registry status: Not yet recruiting
Study type: Interventional
Phase: Phase 1
Sponsor: Bristol-Myers Squibb
Conditions: Idiopathic Inflammatory Myopathies, Lupus Nephritis, Rheumatoid Arthritis, Sjögren's Disease, Systemic Lupus Erythematosus, Systemic Sclerosis

Overview

ClinicalTrials.gov lists this study as Not yet recruiting.

Official title: A Phase 1, Multicenter, Open-Label Study of BMS-986553, CD19 In Vivo Chimeric Antigen Receptor (CAR) T Cells, in Participants With Refractory Autoimmune Diseases

Enrollment: 60 participants (Estimated).

What is being studied

Drug: BMS-986553

Who may be eligible

Ages: 18 Years to no maximum
Sex: All
Healthy volunteers accepted: No

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: * SLE participants: Must have diagnosis of SLE defined as fulfilling the 2019 ACR/EULAR classification criteria of SLE. * IIM participants: Must have diagnosis of IIM defined as fulfilling the 2017 ACR/EULAR classification criteria for probable or definite IIM. * SSc participants: Must have diagnosis of SSc defined as fulfilling 2013 ACR/EULAR classification criteria for SSc. * RA participants: Must have diagnosis of RA, defined as fulfilling 2010 ACR/EULAR criteria for RA. * Primary SjD Participants: Must have diagnosis fulfilling the 2016 ACR/EULAR Classification Criteria. Exclusion Criteria: * Participants must not have other systemic immune disorders. Other protocol-defined Inclusion/Exclusion criteria apply.

Study locations

23 study locations are listed.

Site recruitment status is not specified in the registry data for these locations.

Countries: Belgium, France, Germany, Netherlands, Poland, United States

North Holland, Netherlands: 1
Kuyavian-Pomeranian Voivodeship, Poland: 1
Malopolwksie, Poland: 1
California, United States: 1
Massachusetts, United States: 1
Michigan, United States: 1
Minnesota, United States: 1
Nebraska, United States: 1
New Jersey, United States: 1
New York, United States: 1
Pennsylvania, United States: 1
Utah, United States: 1
Washington, United States: 2

Sample of listed locations

Local Institution - 0029 — Leuven, 3000, Belgium — Site recruitment status not specified in the registry data
Local Institution - 0039 — Montpellier, 34295, France — Site recruitment status not specified in the registry data
Local Institution - 0047 — Paris, 75014, France — Site recruitment status not specified in the registry data
Local Institution - 0028 — Berlin, 10117, Germany — Site recruitment status not specified in the registry data
Local Institution - 0060 — Erlangen, 91054, Germany — Site recruitment status not specified in the registry data
Local Institution - 0059 — Magdeburg, 39120, Germany — Site recruitment status not specified in the registry data
Local Institution - 0027 — Würzburg, 97080, Germany — Site recruitment status not specified in the registry data
Local Institution - 0055 — Amsterdam, North Holland, 1105 AZ, Netherlands — Site recruitment status not specified in the registry data
Local Institution - 0063 — Leiden, 0, Netherlands — Site recruitment status not specified in the registry data
Local Institution - 0051 — Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-168, Poland — Site recruitment status not specified in the registry data
Local Institution - 0050 — Krakow, Malopolwksie, 30-688, Poland — Site recruitment status not specified in the registry data
Local Institution - 0046 — Poznan, 60-569, Poland — Site recruitment status not specified in the registry data
Local Institution - 0064 — Newport Beach, California, 92663, United States — Site recruitment status not specified in the registry data
Local Institution - 0001 — Worcester, Massachusetts, 01655, United States — Site recruitment status not specified in the registry data
Local Institution - 0004 — Ann Arbor, Michigan, 48109, United States — Site recruitment status not specified in the registry data
Local Institution - 0013 — Saint Paul, Minnesota, 55108, United States — Site recruitment status not specified in the registry data
Local Institution - 0062 — Omaha, Nebraska, 68198, United States — Site recruitment status not specified in the registry data
Local Institution - 0007 — Morristown, New Jersey, 07962, United States — Site recruitment status not specified in the registry data
Local Institution - 0052 — Great Neck, New York, 11021, United States — Site recruitment status not specified in the registry data
Local Institution - 0008 — Philadelphia, Pennsylvania, 19104, United States — Site recruitment status not specified in the registry data
Local Institution - 0015 — Salt Lake City, Utah, 84143, United States — Site recruitment status not specified in the registry data
Local Institution - 0003 — Seattle, Washington, 98109, United States — Site recruitment status not specified in the registry data
Local Institution - 0005 — Seattle, Washington, 98104, United States — Site recruitment status not specified in the registry data

Study details

Start date: October 30, 2026
Primary completion date: October 20, 2032
Completion date: January 31, 2033
First posted: October 14, 2026

Source and update information

Source: ClinicalTrials.gov
NCT ID: NCT07873931
Registry last updated: October 14, 2026
QualifiedStudies registry data refreshed: October 19, 2026
QualifiedStudies record fetched: October 19, 2026

View NCT07873931 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Clinical trial FAQ